试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-05-05
Efficacy And Safety Study Of Tanezumab Subcutaneous Administration In Osteoarthritis - A Subcutaneous/Intravenous Bridging Study
编号:NCT01089725登记状态:提前终止企业 / 申办者:Pfizer
药物 / 成分:Placebo IV、Placebo SC、Tanezumab SC、Placebo IV
登记的停止原因(原文):See termination reason in detailed description.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-05-05
First-in-Human and Proof-of-Mechanism Study of ARC19499 Administered to Hemophilia Patients
编号:NCT01191372登记状态:提前终止企业 / 申办者:Baxalta now part of Shire
药物 / 成分:placebo control、ARC19499
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-05-05
Safety Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Lupus Nephritis
编号:NCT01541670登记状态:提前终止企业 / 申办者:Baxalta now part of Shire
药物 / 成分:Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-05-05
Water and Sudafed in Autonomic Failure
编号:NCT02149901登记状态:提前终止企业 / 申办者:Vanderbilt University
药物 / 成分:Pseudoephedrine + 480 ml water、Pseudoephedrine + 50 ml water、Placebo + 480 ml water (optional)、Placebo + 50 ml water (optional)
登记的停止原因(原文):funding terminated
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-05-05
Efficacy and Safety Study of BIIB074 in Participants With Small Fiber Neuropathy
编号:NCT03339336登记状态:提前终止企业 / 申办者:Biogen
药物 / 成分:BIIB074、Placebo
登记的停止原因(原文):Sponsor decision to close study early; not due to safety concerns
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-05-04
Reduced Radiotherapy With Pac/Cis vs Standard Radiotherapy With 5-FU/Cis in Locally Advanced Head and Neck Cancer
编号:NCT01126216登记状态:提前终止企业 / 申办者:University of Erlangen-Nürnberg Medical School
药物 / 成分:Paclitaxel/Cisplatin、Reduced RT、5-FU/Cisplatin、Standard RT
登记的停止原因(原文):After an Interims analysis the Data Safety Monitoring board recommended this because no significant difference between the two arms was seen and was not expected with an reasonable recruitment of patients.
No interruptions of the trial were made.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-05-04
Study of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Type I or II Achalasia
编号:NCT02931565登记状态:提前终止企业 / 申办者:Cyclerion Therapeutics
药物 / 成分:Olinciguat、Matching Placebo
登记的停止原因(原文):The study was prematurely terminated due to enrollment challenges.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-05-03
Trial of High-dose Urso in Primary Sclerosing Cholangitis
编号:NCT00059202登记状态:提前终止企业 / 申办者:National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
药物 / 成分:Ursodeoxycholic Acid、Placebo
登记的停止原因(原文):DSMB reviewed interim analysis and terminated the study due to futility.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-05-03
A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
编号:NCT01098240登记状态:提前终止企业 / 申办者:Pfizer
药物 / 成分:CP-601,927、Placebo
登记的停止原因(原文):See termination reason in detailed description.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-05-03
Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients
编号:NCT02583191登记状态:提前终止企业 / 申办者:AIO-Studien-gGmbH
药物 / 成分:Rivaroxaban、low-molecular heparine
登记的停止原因(原文):Recruitment was not as expected.
查看官方原始记录 ↗